Hemcheck Sweden AB has received a so-called “Intention to Grant” from the European Patent Office, “EPO”, regarding the patent application for its filter solution. This means that the EPO intends to approve the application after certain formal steps have been completed. The patent has previously been approved in Sweden and in the USA.
– I am very pleased that we have taken this important step towards approval of this patent application on the European market. The patent, when approved, will be of great importance as it protects a vital part of our unique technology which enables the fast hemolysis detection in blood samples, says Hemcheck CEO Joen Averstad.
For further information contact:
Hemcheck Sweden AB (publ)
Joen Averstad, CEO
Tel: +46 76 108 8191
Hemcheck Sweden AB, founded in 2010, produces and commercializes a patented CE-marked concept for point of care hemolysis detection. The concept consists of disposable tests as well as readers that can very quickly, directly upon sampling, identify hemolysed blood samples in vacuum tubes and blood gas syringes. Hemolysis, ruptured red blood cells, is the most common reason globally why blood samples cannot be analyzed accurately. Hemcheck’s goal is to contribute to improved healthcare by offering user-friendly services for the detection of hemolysed blood samples in direct connection with blood sampling. By doing so, Hemcheck can contribute to increased patient safety, more efficient processes and lower costs. The company is based in Karlstad and is listed on the Nasdaq First North Growth Market.
FNCA Sweden AB, 08-528 00 399, info@fnca, is the Certified Adviser to the company.